Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.

Dotinurad

Другие языки:

日本語

Dotinurad

Подписчиков: 0, рейтинг: 0

Dotinurad
Clinical data

Trade names	Urece
Other names	FYU-981
Legal status
Legal status	Rx-only (Japan)
Identifiers
IUPAC name (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone
CAS Number	1285572-51-1
PubChem CID	51349053
DrugBank	DB16145
ChemSpider	59718651
UNII	305EB53128
KEGG	D11071
ChEMBL	ChEMBL4594446
Chemical and physical data
Formula	C₁₄H₉Cl₂NO₄S
Molar mass	358.19 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1N(C2=CC=CC=C2S1(=O)=O)C(=O)C3=CC(=C(C(=C3)Cl)O)Cl
InChI InChI=1S/C14H9Cl2NO4S/c15-9-5-8(6-10(16)13(9)18)14(19)17-7-22(20,21)12-4-2-1-3-11(12)17/h1-6,18H,7H2 Key:VOFLAIHEELWYGO-UHFFFAOYSA-N

Dotinurad (Urece) is a drug for the treatment of gout and hyperuricemia. It was developed by Fuji Yakuhin and approved for use in Japan in 2020. The drug is continuing clinical trials by Fortress Biotech and regulatory evaluation for approval in North America and Europe.

Dotinurad acts as a selective urate reabsorption inhibitor that has uric acid lowering activity.